Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Short Interest Report for September

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totaling 2,864,201 shares, a growth of 76.1% from the September 15th total of 1,626,351 shares. Approximately 21.1% of the company’s stock are short sold. Based on an average daily volume of 8,031,092 shares, the days-to-cover ratio is currently 0.4 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Thursday. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vivos Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $2.80.

Vivos Therapeutics Stock Performance

Shares of NASDAQ:VVOS traded down $0.01 during trading on Friday, reaching $0.13. The stock had a trading volume of 1,617,499 shares, compared to its average volume of 5,741,976. Vivos Therapeutics has a 1-year low of $0.13 and a 1-year high of $3.10. The stock has a market cap of $1.82 million, a PE ratio of -0.07 and a beta of 6.11. The business has a fifty day moving average price of $0.20 and a 200-day moving average price of $0.51.

Vivos Therapeutics (NASDAQ:VVOS) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.10. The firm had revenue of $5.15 million for the quarter, compared to analyst estimates of $5.63 million. Vivos Therapeutics had a negative net margin of 122.00% and a negative return on equity of 2,325.64%. Sell-side analysts expect that Vivos Therapeutics will post -1.24 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Vivos Therapeutics stock. Sequoia Financial Advisors LLC purchased a new position in Vivos Therapeutics, Inc. (NASDAQ:VVOS) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 24,000 shares of the company’s stock, valued at approximately $28,000. Sequoia Financial Advisors LLC owned approximately 0.18% of Vivos Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 26.35% of the company’s stock.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on developing and commercializing non-surgical treatments for sleep-related breathing disorders and related craniofacial conditions. The company’s primary focus is obstructive sleep apnea, a disorder in which the upper airway repeatedly narrows or becomes blocked during sleep.

The company markets the Vivos System, a series of customized oral appliances designed to help reposition and support the upper airway. Its offerings include the Vivos Complete Airway Repositioning Appliance (CARE) and other dental devices intended to improve airway function during sleep.